50 related articles for article (PubMed ID: 7564529)
21. A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan.
Tamura K
Semin Hematol; 1996 Oct; 33(4 Suppl 3):2-11. PubMed ID: 8916310
[TBL] [Abstract][Full Text] [Related]
22. Interactions of N-desmethyl imatinib, an active metabolite of imatinib, with P-glycoprotein in human leukemia cells.
Mlejnek P; Dolezel P; Faber E; Kosztyu P
Ann Hematol; 2011 Jul; 90(7):837-42. PubMed ID: 21225261
[TBL] [Abstract][Full Text] [Related]
23. P-glycoprotein and survivin simultaneously regulate vincristine-induced apoptosis in chronic myeloid leukemia cells.
Souza PS; Vasconcelos FC; De Souza Reis FR; Nestal De Moraes G; Maia RC
Int J Oncol; 2011 Oct; 39(4):925-33. PubMed ID: 21720708
[TBL] [Abstract][Full Text] [Related]
24. Effect of S9788, cyclosporin A and verapamil on intracellular distribution of THP-doxorubicin in multidrug-resistant K562 tumor cells, as studied by laser confocal microspectrofluorometry.
Sebille S; Morjani H; Poullain MG; Manfait M
Anticancer Res; 1994; 14(6A):2389-93. PubMed ID: 7825978
[TBL] [Abstract][Full Text] [Related]
25. Idarubicin in acute leukemia: results of US trials.
Berman E; Raymond V; Gee TS; Kempin SJ; Gulati S; Andreeff M; Gabrilove J; Young CW; Clarkson BD; Wiernik PH
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():49. PubMed ID: 2713561
[No Abstract] [Full Text] [Related]
26. Targeting activating transcription factor 3 by Galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia.
Kuroda J; Yamamoto M; Nagoshi H; Kobayashi T; Sasaki N; Shimura Y; Horiike S; Kimura S; Yamauchi A; Hirashima M; Taniwaki M
Mol Cancer Res; 2010 Jul; 8(7):994-1001. PubMed ID: 20571063
[TBL] [Abstract][Full Text] [Related]
27. BCR-ABL(T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge?
Legros L; Hayette S; Nicolini FE; Raynaud S; Chabane K; Magaud JP; Cassuto JP; Michallet M
Leukemia; 2007 Oct; 21(10):2204-6. PubMed ID: 17541396
[No Abstract] [Full Text] [Related]
28. Comparative study of DNA damage, cell cycle and apoptosis in human K562 and CCRF-CEM leukemia cells: role of BCR/ABL in therapeutic resistance.
Pytel D; Wysocki T; Majsterek I
Comp Biochem Physiol C Toxicol Pharmacol; 2006 Sep; 144(1):85-92. PubMed ID: 16904383
[TBL] [Abstract][Full Text] [Related]
29. [A pharmacokinetic study of idarubicin hydrochloride, a new anthracycline anti-tumor drug, in patients with acute leukemia. Idarubicin Study Group].
Fujita H; Ogawa M; Masaoka T; Yamada K; Kimura K
Gan To Kagaku Ryoho; 1992 Jun; 19(6):791-8. PubMed ID: 1605655
[TBL] [Abstract][Full Text] [Related]
30. Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1.
Yamada O; Ozaki K; Furukawa T; Machida M; Wang YH; Motoji T; Mitsuishi T; Akiyama M; Yamada H; Kawauchi K; Matsuoka R
Cell Signal; 2011 Jul; 23(7):1119-27. PubMed ID: 21356308
[TBL] [Abstract][Full Text] [Related]
31. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier.
Hendrikse NH; de Vries EG; Eriks-Fluks L; van der Graaf WT; Hospers GA; Willemsen AT; Vaalburg W; Franssen EJ
Cancer Res; 1999 May; 59(10):2411-6. PubMed ID: 10344751
[TBL] [Abstract][Full Text] [Related]
32. Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia.
Schlenk RF; Hartmann F; Hensel M; Jung W; Weber-Nordt R; Gabler A; Haas R; Ho AD; Trümper L; Döhner H
Leukemia; 2002 Apr; 16(4):581-6. PubMed ID: 11960336
[TBL] [Abstract][Full Text] [Related]
33. Reversal of multidrug resistance to epirubicin by cyclosporin A in liposomes or intralipid.
Lo YL; Liu FI; Yang JM; Cherng JY
Anticancer Res; 2001; 21(1A):445-50. PubMed ID: 11299776
[TBL] [Abstract][Full Text] [Related]
34. Sub-lethal Camphor Exposure Triggers Oxidative Stress, Cardiotoxicity, and Cardiac Physiology Alterations in Zebrafish Embryos.
Du ZC; Xia ZS; Zhang MZ; Wei YT; Malhotra N; Saputra F; Audira G; Roldan MJM; Hsiao CD; Hao EW; Hou XT; Deng JG
Cardiovasc Toxicol; 2021 Nov; 21(11):901-913. PubMed ID: 34339023
[TBL] [Abstract][Full Text] [Related]
35. The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery.
Bardelmeijer HA; van Tellingen O; Schellens JH; Beijnen JH
Invest New Drugs; 2000 Aug; 18(3):231-41. PubMed ID: 10958591
[TBL] [Abstract][Full Text] [Related]
36. P170-related multidrug resistance. Enhancement of idarubicin content in leukemic cells with cyclosporin in vivo: a report of two cases.
Damiani D; Michieli M; Michelutti A; Pea F; Baraldo M; Fanin R; Russo D; Furlanut M; Baccarani M
Leukemia; 1995 Oct; 9(10):1792-5. PubMed ID: 7564529
[No Abstract] [Full Text] [Related]
37. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate.
Illmer T; Schaich M; Platzbecker U; Freiberg-Richter J; Oelschlägel U; von Bonin M; Pursche S; Bergemann T; Ehninger G; Schleyer E
Leukemia; 2004 Mar; 18(3):401-8. PubMed ID: 14724652
[TBL] [Abstract][Full Text] [Related]
38. Clinical approach to circumvention of multidrug resistance in refractory leukemic patients: association of cyclosporin A with etoposide.
Maia RC; Carriço MK; Klumb CE; Noronha H; Coelho AM; Vasconcelos FC; Ruimanek VM
J Exp Clin Cancer Res; 1997 Dec; 16(4):419-24. PubMed ID: 9505216
[TBL] [Abstract][Full Text] [Related]
39. P170 glycoprotein expression and impaired anthracycline retention in chronic myeloid leukaemia.
Damiani D; Michieli M; Michelutti A; Fanin R; Russo D; Baccarani M
Leuk Lymphoma; 1995 Apr; 17(3-4):289-94. PubMed ID: 8580798
[TBL] [Abstract][Full Text] [Related]
40. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells.
Mankhetkorn S; Dubru F; Hesschenbrouck J; Fiallo M; Garnier-Suillerot A
Mol Pharmacol; 1996 Mar; 49(3):532-9. PubMed ID: 8643093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
